Research and Development Prepaid Expenses and Accrued Liabilities |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
| Research and Development Prepaid Expenses and Accrued Liabilities | Research and Development Prepaid Expenses and Accrued Liabilities Included within prepaid expenses and other current assets at June 30, 2025 and December 31, 2024 is $8,155 and $8,338, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at June 30, 2025 and December 31, 2024 is $24,584 and $17,441, respectively, relating to research and development expenditures. These amounts are determined based on the estimated costs to complete each study or activity related to the ongoing clinical trials for ivonescimab, the estimation of the current stage of completion and the invoices received, as well as predetermined milestones which are not reflective of the current stage of development for prepaid expenses. However, accrued liabilities increase as the activities progress. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company’s operational knowledge of the work completed under those contracts.
|